JACKSONVILLE: Suven Life Sciences said it has received five product patents for their drug in Europe, Hong Kong, Israel, Australia and Norway for the treatment of disorders associated with neuro-degenerative diseases.
“The grant of 1 product patent from Australia, one from Europe, one from Hong Kong, one from Israel and one from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases,” Suven Life Sciences said in a BSE filing…